Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Published:2020-01-09 Issue:2 Volume:382 Page:140-151
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Fenaux Pierre¹,Platzbecker Uwe¹,Mufti Ghulam J.¹,Garcia-Manero Guillermo¹,Buckstein Rena¹,Santini Valeria¹,Díez-Campelo María¹,Finelli Carlo¹,Cazzola Mario¹^ORCID,Ilhan Osman¹,Sekeres Mikkael A.¹,Falantes José F.¹,Arrizabalaga Beatriz¹,Salvi Flavia¹,Giai Valentina¹,Vyas Paresh¹,Bowen David¹,Selleslag Dominik¹,DeZern Amy E.¹,Jurcic Joseph G.¹,Germing Ulrich¹,Götze Katharina S.¹,Quesnel Bruno¹,Beyne-Rauzy Odile¹,Cluzeau Thomas¹,Voso Maria-Teresa¹,Mazure Dominiek¹,Vellenga Edo¹,Greenberg Peter L.¹,Hellström-Lindberg Eva¹,Zeidan Amer M.¹,Adès Lionel¹,Verma Amit¹,Savona Michael R.¹,Laadem Abderrahmane¹,Benzohra Aziz¹,Zhang Jennie¹,Rampersad Anita¹,Dunshee Diana R.¹^ORCID,Linde Peter G.¹,Sherman Matthew L.¹,Komrokji Rami S.¹,List Alan F.¹

Affiliation:

1. From Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d’Azur, Département d’Hématologie Clinique, CHU Nice, Nice (T.C.) — all in France; Medical Clinic and Policlinic 1,...

Funder

Celgene in collaboration with Acceleron

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1908892

Cited by 365 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes;The Lancet Haematology;2024-09

2. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

3. Progress in Lower-Risk MDS;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial;The Lancet Haematology;2024-09

5. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28